Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Jos, Beijnen"'
Autor:
John Haanen, Arief Lalmohamed, Jos Beijnen, Marjolein Metselaar-Albers, Irma Meijerman, Ferdi Engels
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background The role of antibiotics in malignancies treated with immune checkpoint inhibitors (ICI) remains unclear. Several studies suggested a detrimental impact of antibiotic use on the response to ICI, but were susceptible to confounding by indica
Externí odkaz:
https://doaj.org/article/fe1cb478e39442389d268f3b42a38ee0
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 2, Pp 258-268 (2023)
Abstract Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapol
Externí odkaz:
https://doaj.org/article/aaf34c4b3c5a4baf998072fbc42281c1
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties
Externí odkaz:
https://doaj.org/article/e3f8577820e144b5a99f96a9d9b330bb
Autor:
Nienke E van Trommel, Gemma G Kenter, John Haanen, Tanja D de Gruijl, Sanne Samuels, Ekaterina S Jordanova, Ton Schumacher, Joost H van den Berg, Bastiaan Nuijen, Jos Beijnen, Marc van Beurden, Noor Alida Maria Bakker, Jossie Rotman, Henry J MAA Zijlmans, Maartje van Ruiten, Karin De Visser
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Usual vulvar intraepithelial neoplasia (uVIN) is a premalignancy caused by persistent infection with high-risk types of human papillomavirus (HPV), mainly type 16. Even though different treatment modalities are available (eg, surgical exci
Externí odkaz:
https://doaj.org/article/c29336b4129f4a6a8b7b92a61e5b1b59
Publikováno v:
Clinical and Translational Science. 16:258-268
Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapolation fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daaeaa6311168b819386fed37275eedf
https://doi.org/10.1111/cts.13446
https://doi.org/10.1111/cts.13446
Autor:
Piet Borst, Jos Beijnen, Jan Wijnholds, Koen van de Wetering, Marcel de Haas, Hiroaki Yamaguchi, Robert Jansen, Cornelia de Wolf
Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57cbc9558c31ff26fc627ab14998cadb
https://doi.org/10.1158/1535-7163.22484769.v1
https://doi.org/10.1158/1535-7163.22484769.v1
Autor:
Piet Borst, Jos Beijnen, Jan Wijnholds, Koen van de Wetering, Marcel de Haas, Hiroaki Yamaguchi, Robert Jansen, Cornelia de Wolf
We have studied the potential contribution of ABCG2 (breast cancer resistance protein) to resistance to nucleoside analogues. In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d2d22d4d45a532d81d5a9127881e89
https://doi.org/10.1158/1535-7163.c.6531576.v1
https://doi.org/10.1158/1535-7163.c.6531576.v1
Autor:
Piet Borst, Jos Beijnen, Jan Wijnholds, Koen van de Wetering, Marcel de Haas, Hiroaki Yamaguchi, Robert Jansen, Cornelia de Wolf
Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51feb4ff394c169fcf158ae9af34a8ad
https://doi.org/10.1158/1535-7163.22484772
https://doi.org/10.1158/1535-7163.22484772
Publikováno v:
International Journal of Molecular Sciences. 23:9866
Ritonavir is the most potent cytochrome P450 (CYP) 3A4 inhibitor in clinical use and is often applied as a booster for drugs with low oral bioavailability due to CYP3A4-mediated biotransformation, as in the treatment of HIV (e.g., lopinavir/ritonavir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35190abf3b8dbc4f2839472287fded19
https://doi.org/10.3390/ijms23179866
https://doi.org/10.3390/ijms23179866
Autor:
Sanne, Huijberts, Liqin, Wang, Rodrigo Leite, de Oliveira, Hilde, Rosing, Bastiaan, Nuijen, Jos, Beijnen, Rene, Bernards, Jan, Schellens, Sofie, Wilgenhof
Publikováno v:
Future oncology (London, England). 16(11)
The clinical benefit of treatment with BRAF- and MEK-inhibitors in melanoma is limited due to resistance associated with emerging secondary mutations. Preclinical and clinical studies have shown that short-term treatment with the HDAC inhibitor vorin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8d8160554496c99f94fa61bc394a3fc6
https://pubmed.ncbi.nlm.nih.gov/32125175
https://pubmed.ncbi.nlm.nih.gov/32125175